NTLA
Income statement / Annual
Last year (2024), Intellia Therapeutics, Inc.'s total revenue was $57.88 M,
an increase of 59.55% from the previous year.
In 2024, Intellia Therapeutics, Inc.'s net income was -$519.02 M.
See Intellia Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$57.88 M |
$36.28 M |
$52.12 M |
$33.05 M |
$57.99 M |
$43.10 M |
$30.43 M |
$26.12 M |
$16.48 M |
$6.04 M |
| Cost of Revenue |
$0.00
|
$8.98 M
|
$7.57 M
|
$6.89 M
|
$150.41 M
|
$108.41 M
|
$89.12 M
|
$67.65 M
|
$31.84 M
|
$11.17 M
|
| Gross Profit |
$57.88 M
|
$27.30 M
|
$44.55 M
|
$26.16 M
|
-$92.41 M
|
-$65.31 M
|
-$58.68 M
|
-$41.53 M
|
-$15.36 M
|
-$5.13 M
|
| Gross Profit Ratio |
1
|
0.75
|
0.85
|
0.79
|
-1.59
|
-1.52
|
-1.93
|
-1.59
|
-0.93
|
-0.85
|
| Research and Development Expenses |
$466.31 M
|
$435.07 M
|
$419.98 M
|
$229.81 M
|
$150.41 M
|
$108.41 M
|
$89.12 M
|
$67.65 M
|
$31.84 M
|
$11.17 M
|
| General & Administrative Expenses |
$125.83 M
|
$116.50 M
|
$90.31 M
|
$71.10 M
|
$44.17 M
|
$41.06 M
|
$32.19 M
|
$28.03 M
|
$16.80 M
|
$8.28 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$125.83 M
|
$116.50 M
|
$90.31 M
|
$71.10 M
|
$44.17 M
|
$41.06 M
|
$32.19 M
|
$28.03 M
|
$16.80 M
|
$8.28 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$592.14 M
|
$551.57 M
|
$510.29 M
|
$300.90 M
|
$194.58 M
|
$149.47 M
|
$121.30 M
|
$95.67 M
|
$48.64 M
|
$19.45 M
|
| Cost And Expenses |
$592.14 M
|
$551.57 M
|
$510.29 M
|
$300.90 M
|
$194.58 M
|
$149.47 M
|
$121.30 M
|
$95.67 M
|
$48.64 M
|
$19.45 M
|
| Interest Income |
$47.81 M
|
$49.83 M
|
$8.54 M
|
$1.28 M
|
$2.35 M
|
$6.84 M
|
$5.53 M
|
$2.01 M
|
$525,000.00
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$8.54 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$10.29 M
|
$8.98 M
|
$7.57 M
|
$6.89 M
|
$6.31 M
|
$5.59 M
|
$4.46 M
|
$2.99 M
|
$1.10 M
|
$328,000.00
|
| EBITDA |
-$523.98 M |
-$506.32 M |
-$450.59 M |
-$260.96 M |
-$130.27 M |
-$100.78 M |
-$86.41 M |
-$66.56 M |
-$31.06 M |
-$13.08 M |
| EBITDA Ratio |
-9.05
|
-13.96
|
-8.53
|
-8.1
|
-2.36
|
-2.34
|
-2.99
|
-2.66
|
-1.95
|
-2.16
|
| Operating Income Ratio |
-9.23
|
-14.21
|
-8.79
|
-8.1
|
-2.36
|
-2.47
|
-2.99
|
-2.66
|
-1.95
|
-2.22
|
| Total Other Income/Expenses Net |
$15.24 M
|
$34.10 M
|
-$16.02 M
|
-$42,000.00
|
$2.35 M
|
$6.84 M
|
$5.53 M
|
$2.01 M
|
$525,000.00
|
$0.00
|
| Income Before Tax |
-$519.02 M
|
-$481.19 M
|
-$474.19 M
|
-$267.89 M
|
-$134.23 M
|
-$99.53 M
|
-$85.34 M
|
-$67.54 M
|
-$31.63 M
|
-$13.41 M
|
| Income Before Tax Ratio |
-8.97
|
-13.27
|
-9.1
|
-8.1
|
-2.31
|
-2.31
|
-2.8
|
-2.59
|
-1.92
|
-2.22
|
| Income Tax Expense |
$0.00
|
$0.00
|
$16.02 M
|
-$8.17 M
|
-$8.66 M
|
-$6.84 M
|
$5.53 M
|
-$2.99 M
|
-$1.10 M
|
-$1.01 M
|
| Net Income |
-$519.02 M
|
-$481.19 M
|
-$490.21 M
|
-$259.72 M
|
-$125.57 M
|
-$92.70 M
|
-$85.34 M
|
-$67.54 M
|
-$31.63 M
|
-$12.40 M
|
| Net Income Ratio |
-8.97
|
-13.27
|
-9.41
|
-7.86
|
-2.17
|
-2.15
|
-2.8
|
-2.59
|
-1.92
|
-2.05
|
| EPS |
-5.25 |
-5.42 |
-6.37 |
-3.66 |
-2.24 |
-1.96 |
-1.98 |
-1.88 |
-1.42 |
-0.7 |
| EPS Diluted |
-5.25 |
-5.42 |
-6.37 |
-3.66 |
-2.24 |
-1.96 |
-1.98 |
-1.88 |
-1.42 |
-0.7 |
| Weighted Average Shares Out |
$98.85 M
|
$88.77 M
|
$76.97 M
|
$70.89 M
|
$55.99 M
|
$47.25 M
|
$43.07 M
|
$36.01 M
|
$22.22 M
|
$17.66 M
|
| Weighted Average Shares Out Diluted |
$98.85 M
|
$88.77 M
|
$76.97 M
|
$70.89 M
|
$55.99 M
|
$47.25 M
|
$43.07 M
|
$36.01 M
|
$22.22 M
|
$17.66 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
